HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC.

Abstract
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
AuthorsJason E Faris, M Dror Michaelson
JournalNature reviews. Clinical oncology (Nat Rev Clin Oncol) Vol. 7 Issue 1 Pg. 7-8 (Jan 2010) ISSN: 1759-4782 [Electronic] England
PMID20029441 (Publication Type: Comment, Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: